Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00262301 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema
Angioneurotic Edema
Genetic Disorders

Interventions

DRUG: recombinant human C1 inhibitor
DRUG: Placebo

Sponsor

Pharming Technologies B.V.